

**ROSWELL PARK CANCER INSTITUTE CORPORATION
TECHNOLOGY TRANSFER COMMITTEE
OF THE BOARD OF DIRECTORS**

A meeting of the Technology Transfer Committee of the Board of Directors of Roswell Park Cancer Institute Corporation was held on Wednesday, April 20, 2017 at 8:30 a.m. in the Patrick Lee Conference Room, 9th Floor, Scott Bieler Clinical Services Center of the Institute.

Present: Nora. B. Sullivan – Chairperson
June W. Hoeflich
Kenneth Manning
Noah Rifkin
R. Buford Sears
Candace S. Johnson, PhD, President & Chief Executive Officer
Joseph Dunn, PhD

Excused: Michael L. Joseph, Chairman of the Board

Present by Invitation: Michael B. Sexton, Esq., Chief Administrative Officer and General Counsel – Secretary
Gregory McDonald, Chief Financial Officer
Camille Wicher, Ph.D., Esq. MSN, RN, Vice President of Corporate Ethics and Research Subject Protection
Harl Tolbert, Director of Technology Transfer & Commercial Development
Betsy Doty, Administrator to the Board of Directors
Thomas Schwaab, MD, PhD, Chief of Strategy, Business Development and Outreach
David Donovan, Senior Executive Director of Business Development
Ericka N. Bennett, Esq., Associate General Counsel
Kristen Castner, Intellectual Property Manager
Patrick Emmerling, Senior Licensing Manager

Ms. Sullivan opened the meeting and thanked all for attending the meeting.

Ms. Sullivan asked for a motion to approve the November minutes which was made by Mr. Manning and seconded by Mr. Rifkin. The motion was unanimously approved.

Mr. Manning then made a motion to move the meeting into to Executive Session to discuss the license agreement being negotiated between Mimivax LLC and Roswell Park Cancer Institute, as well as an update on the status of business arrangements for Roswell Park Cancer Institute's licensee, Tactiva LLC, the status of Roswell Park Cancer Institute start-ups and benchmarking strategies. The motion was seconded by Mr. Rifkin and was unanimously approved.


Mr. Tolbert provided history and update on the status of license negotiations with Mimivax, LLC, and board members provided Mr. Tolbert with direction concerning the negotiation of the sublicensing royalty rate. Dr. Johnson provided an update on the business plan,

staffing and investment for OmniSeq LLC. Mr. Tolbert provided an update on start-ups, including the Witness Cares program proposal to establish a start-up. Mr. Tolbert provided an update on matters involving licensees, Tracon, and Generate BioMed.

A motion was made by Mr. Dunn and seconded by Mr. Manning to return to Open Session, which was seconded and unanimously approved.

There being no further business, the meeting was duly adjourned.

Respectfully submitted,


Michael B. Sexton, Esq.